This company has been marked as potentially delisted and may not be actively trading. Cesca Therapeutics (KOOL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendOwnershipTrendsBuy This Stock KOOL vs. THMO, BMEA, IKT, SKYE, FBIO, QIPT, STTK, HYPR, FATE, and ANIXShould you be buying Cesca Therapeutics stock or one of its competitors? The main competitors of Cesca Therapeutics include ThermoGenesis (THMO), Biomea Fusion (BMEA), Inhibikase Therapeutics (IKT), Skye Bioscience (SKYE), Fortress Biotech (FBIO), Quipt Home Medical (QIPT), Shattuck Labs (STTK), Hyperfine (HYPR), Fate Therapeutics (FATE), and Anixa Biosciences (ANIX). These companies are all part of the "medical" sector. Cesca Therapeutics vs. Its Competitors ThermoGenesis Biomea Fusion Inhibikase Therapeutics Skye Bioscience Fortress Biotech Quipt Home Medical Shattuck Labs Hyperfine Fate Therapeutics Anixa Biosciences Cesca Therapeutics (NASDAQ:KOOL) and ThermoGenesis (NASDAQ:THMO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Is KOOL or THMO more profitable? ThermoGenesis has a net margin of 0.00% compared to Cesca Therapeutics' net margin of -98.84%. ThermoGenesis' return on equity of 0.00% beat Cesca Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cesca Therapeutics-98.84% -77.30% -37.75% ThermoGenesis N/A N/A N/A Which has more risk & volatility, KOOL or THMO? Cesca Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, ThermoGenesis has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Do institutionals and insiders have more ownership in KOOL or THMO? 3.1% of Cesca Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are owned by institutional investors. 68.9% of Cesca Therapeutics shares are owned by company insiders. Comparatively, 78.0% of ThermoGenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to KOOL or THMO? In the previous week, Cesca Therapeutics' average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score. Company Overall Sentiment Cesca Therapeutics Neutral ThermoGenesis Neutral Which has stronger valuation & earnings, KOOL or THMO? ThermoGenesis has lower revenue, but higher earnings than Cesca Therapeutics. Cesca Therapeutics is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCesca Therapeutics$9.67M3.18-$39.72M-$3.60-3.53ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A SummaryThermoGenesis beats Cesca Therapeutics on 8 of the 10 factors compared between the two stocks. Get Cesca Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KOOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOOL vs. The Competition Export to ExcelMetricCesca TherapeuticsLaboratory Apparatus & Furniture IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.73M$1K$6.12B$10.53BDividend Yield0.50%N/A5.51%4.67%P/E Ratio-3.53N/A85.7226.88Price / Sales3.180.00581.25184.02Price / CashN/AN/A26.3031.10Price / Book4.09N/A13.226.67Net Income-$39.72M-$17.98M$3.30B$276.44M Cesca Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KOOLCesca TherapeuticsN/A$12.72+0.4%N/A+17.7%$30.73M$9.67M-3.5353THMOThermoGenesisN/A$0.00+∞N/AN/A$1K$9.61M0.0040Gap UpBMEABiomea Fusion3.4093 of 5 stars$1.99-2.0%$14.80+643.7%-74.5%$120.80MN/A-0.6650Trending NewsOptions VolumeGap DownIKTInhibikase Therapeutics1.3575 of 5 stars$1.62-3.6%$6.50+301.2%+28.6%$120.72MN/A-0.616SKYESkye Bioscience2.7341 of 5 stars$3.69-5.1%$14.75+299.7%-46.5%$120.54MN/A-3.4811Trending NewsAnalyst DowngradeGap UpFBIOFortress Biotech2.7052 of 5 stars$3.65-8.8%$16.50+352.1%+90.8%$119.02M$57.67M-3.48170QIPTQuipt Home Medical1.9249 of 5 stars$2.73+0.4%$3.15+15.4%-8.2%$118.17M$245.91M-11.371,200Positive NewsSTTKShattuck Labs3.572 of 5 stars$2.39-2.4%$4.00+67.4%+112.3%$117.36M$5.72M-1.98100Positive NewsHYPRHyperfine1.1001 of 5 stars$1.46-2.0%$1.28-12.1%+53.5%$117.09M$12.89M-2.81190News CoveragePositive NewsFATEFate Therapeutics3.982 of 5 stars$0.97-4.0%$3.30+240.2%-56.2%$116.48M$13.63M-0.67550Positive NewsANIXAnixa Biosciences2.6389 of 5 stars$3.42-2.0%$9.00+163.2%+3.2%$114.88M$210K-9.775News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies THMO Alternatives BMEA Alternatives IKT Alternatives SKYE Alternatives FBIO Alternatives QIPT Alternatives STTK Alternatives HYPR Alternatives FATE Alternatives ANIX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOOL) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cesca Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
